Skin Cancer

SKIN CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Nivolumab Plus Ipilimumab in Advanced Melanoma Improves Survival at 5-Year Follow-Up — but Significant Toxicities Linger

A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.
Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines

A small study on patients with metastatic melanoma who were treated with autologous vaccines in a phase 2 clinical trial suggests that soluble PD-1 may have potential as a prognostic biomarker.
The Disappointing Reality of Crowdfunding Cancer Care

If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Some Targeted Therapies May Miss the Mark

Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens

Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.

VIDEO SERIES

Recent Advances in Melanoma Therapy

Targeted Treatments and Immunotherapies for Melanoma

Tailoring Treatments in Melanoma

Drug Resistance in Melanoma

Affordability of Melanoma Care

Melanoma: Treatment-induced Toxicity

Immunotherapy: A Decade of Improvements in Melanoma

Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

Melanoma: Checkpoints in the Pipeline

Targeting Therapy for Melanoma Subtypes

Melanoma: Targetable Genes in the Pipeline

Clinical Trials in Melanoma

SKIN CANCER NEWS

Immune Checkpoint

Eosinophilic Fasciitis: A Rare Immune-Related Adverse Effect of Immune Checkpoint Inhibitor Therapy

December 4, 2019

Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.

Incidence of Squamous Cell Carcinoma of the Anus Increasing

November 21, 2019

A clinician uses a flow cytometer.

Use of Artificial Intelligence on Camera-Based Images of Skin Lesions Shows Promise in the Diagnosis of Melanoma

November 6, 2019

Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of

Bariatric Surgery Linked to Reduced Risk for Skin Cancer

November 1, 2019

Circulating tumor DNA conveyed prognosis among patients with high-risk stage III melanoma, reinforcing the need to include this measure in clinical trial design.

Expert Second Opinions Up Reliability of Melanoma Diagnosis

October 23, 2019

Next post in Skin Cancer

Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.

Incidence of Squamous Cell Carcinoma of the Anus Increasing